Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. (ENTA) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Enanta Pharmaceuticals, Inc. (ENTA), covering cash flow, earnings, and balance sheets.
Enanta Pharmaceuticals, Inc. (ENTA) Income Statement & Financial Overview
Review Enanta Pharmaceuticals, Inc. ENTA income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $16.96M | $14.61M | $17.97M | $17.05M |
| Cost of Revenue | $889000.00 | $0.00 | $0.00 | $621000.00 |
| Gross Profit | $16.07M | $14.61M | $17.97M | $16.43M |
| Gross Profit Ratio | $0.95 | $1.00 | $1.00 | $0.96 |
| R&D Expenses | $27.66M | $30.78M | $28.74M | $35.59M |
| SG&A Expenses | $12.85M | $13.68M | $13.41M | $14.23M |
| Operating Expenses | $40.50M | $44.46M | $42.16M | $49.82M |
| Total Costs & Expenses | $40.50M | $44.46M | $42.16M | $49.82M |
| Interest Income | $2.80M | $3.18M | $3.49M | $3.81M |
| Interest Expense | $1.96M | $2.58M | $2.35M | $2.56M |
| Depreciation & Amortization | $889000.00 | $479000.00 | $594000.00 | $621000.00 |
| EBITDA | -$19.86M | -$26.13M | -$20.10M | -$28.34M |
| EBITDA Ratio | -$1.17 | -$1.79 | -$1.12 | -$1.66 |
| Operating Income | -$23.54M | -$29.85M | -$24.18M | -$32.77M |
| Operating Income Ratio | -$1.39 | -$2.04 | -$1.35 | -$1.92 |
| Other Income/Expenses (Net) | $837000.00 | $668000.00 | $1.13M | $1.25M |
| Income Before Tax | -$22.71M | -$29.19M | -$23.05M | -$31.52M |
| Income Before Tax Ratio | -$1.34 | -$2.00 | -$1.28 | -$1.85 |
| Income Tax Expense | -$416000.00 | -$363000.00 | -$395000.00 | -$363000.00 |
| Net Income | -$22.29M | -$28.82M | -$22.66M | -$31.16M |
| Net Income Ratio | -$1.31 | -$1.97 | -$1.26 | -$1.83 |
| EPS | -$1.05 | $0.00 | -$1.07 | -$1.47 |
| Diluted EPS | -$1.05 | $0.00 | -$1.07 | -$1.47 |
| Weighted Avg Shares Outstanding | $21.24M | $0.00 | $21.18M | $21.17M |
| Weighted Avg Shares Outstanding (Diluted) | $21.24M | $0.00 | $21.18M | $21.17M |
Over the last four quarters, Enanta Pharmaceuticals, Inc. achieved steady financial progress, growing revenue from $17.05M in Q2 2024 to $16.96M in Q1 2025. Gross profit stayed firm with margins at 95% in Q1 2025 versus 96% in Q2 2024. Operating income totaled -$23.54M in Q1 2025, maintaining a -139% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$19.86M. Net income rose to -$22.29M, with EPS at -$1.05. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan